Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Parkinson's Disease

  Free Subscription


1 Exp Neurol
1 J Biol Chem
2 J Neurochem
1 Lancet Neurol
2 Mov Disord
1 Neurobiol Dis
1 Neurology
2 PLoS Genet
2 Rev Neurol (Paris)

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Exp Neurol

  1. LAPPIN JM, Darke S
    Methamphetamine and heightened risk for early-onset stroke and Parkinson's disease: A review.
    Exp Neurol. 2021 Jun 21:113793. doi: 10.1016/j.expneurol.2021.113793.
    PubMed         Abstract available

    J Biol Chem

  2. AMIREDDY N, Puttapaka SN, Vinnakota RL, Ravuri HG, et al
    Correction: The unintended mitochondrial uncoupling effects of the FDA-approved anti-helminth drug nitazoxanide mitigates experimental parkinsonism in mice.
    J Biol Chem. 2021;297:100864.

    J Neurochem

  3. PISCHEDDA F, Piccoli G
    LRRK2 at the pre-synaptic site: A 16-years perspective.
    J Neurochem. 2021;157:297-311.
    PubMed         Abstract available

    Alpha-Synuclein oligomerization and aggregation: All models are useful but only if we know what they model: This is the reply to a comment "Alpha-synuclein oligomerization and aggregation: A model will always be a model" on the original article "Monit
    J Neurochem. 2021;157:891-898.
    PubMed         Abstract available

    Lancet Neurol

  5. VIJIARATNAM N, Simuni T, Bandmann O, Morris HR, et al
    Progress towards therapies for disease modification in Parkinson's disease.
    Lancet Neurol. 2021;20:559-572.
    PubMed         Abstract available

    Mov Disord

  6. PATEL SG, Buchanan CM, Mulroy E, Simpson M, et al
    Potential PINK1 Founder Effect in Polynesia Causing Early-Onset Parkinson's Disease.
    Mov Disord. 2021 Jun 22. doi: 10.1002/mds.28665.

    Counting What Counts: How to Reach Outcomes That Truly Matter to Parkinson's Patients.
    Mov Disord. 2021;36:1290-1292.

    Neurobiol Dis

  8. ANDREOLI L, Abbaszadeh M, Cao X, Cenci MA, et al
    Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism.
    Neurobiol Dis. 2021 Jun 18:105429. doi: 10.1016/j.nbd.2021.105429.
    PubMed         Abstract available


  9. Cross-Sectional Profile of Most Bothersome Problems as Reported Directly by Individuals With Parkinson's Disease (2697).
    Neurology. 2021 Jun 22. pii: WNL.0000000000012412.

    PLoS Genet

  10. SARKAR S, Olsen AL, Sygnecka K, Lohr KM, et al
    alpha-synuclein impairs autophagosome maturation through abnormal actin stabilization.
    PLoS Genet. 2021;17:e1009359.
    PubMed         Abstract available

  11. JEWETT KA, Thomas RE, Phan CQ, Lin B, et al
    Glucocerebrosidase reduces the spread of protein aggregation in a Drosophila melanogaster model of neurodegeneration by regulating proteins trafficked by extracellular vesicles.
    PLoS Genet. 2021;17:e1008859.
    PubMed         Abstract available

    Rev Neurol (Paris)

  12. FERNANDEZ-RODRIGUEZ B, Dupouy J, Harroch E, Fabre-Delcros MH, et al
    Body mass index variations in patients with Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion: A case control study versus standard of care and subthalamic nucleus deep brain stimulation.
    Rev Neurol (Paris). 2021 Jun 18. pii: S0035-3787(21)00562.
    PubMed         Abstract available

  13. CHEVAL M, Villain C, Gay P, Tomeo C, et al
    A case of type 1 achalasia associated with Parkinson's disease.
    Rev Neurol (Paris). 2021 Jun 18. pii: S0035-3787(21)00560.

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.